The annual congress of the EANM (European Association of Nuclear Médecine) is the world’s leading event in nuclear medicine. This itinerant congress has welcomed the participation of Wallonia Export & Investment Agency (AWEX) since 2017. This year, it will be held in Barcelona from October 4 to 8, with the presence of nine Walloon companies representative of the region’s strong ecosystem in this field.
Unique value chain in Wallonia
The nuclear medicine industry relies on the use of radioactivity to diagnose and treat certain diseases. It encompasses nuclear imagery, dosimetry, radiopharmacy, equipment for isotopes (cyclotrons) and biomarkers (synthesizers) productio. Wallonia has established a unique nuclear medicine value chain, notably in isotope production, radiolabeling techniques, radiopharmacy, dosimetry, clinical applications, logistics, education, and training. Wallonia ranks among the world’s top five producers of medical radioisotopes.
Wallonia ecosystem: strengths and opportunities
Key assets of the Walloon ecosystem include a long-standing expertise and technological leadership in radioisotope and radiopharmaceutical production equipment, a dense network of actors and a comprehensive system including logistics, advanced clinical research in new nuclear therapies, as well as academic expertise and dedicated university certificates. Also notable is the recognized expertise of the AFCN (Federal Agency for Nuclear Control). Moreover, Belgium has a high density of nuclear imaging equipment and therefore a high concentration of specialists. The sector benefits from continuous technological innovation supported by significant public and private investments.
As far as collaboration opportunities with Wallonia-based companies go, they include different radioisotope production projects (with the associated public funding), an increasing interest for big pharma and specialized funds, and the ambition of the Region to become a hub for radiopharmaceutical innovation.
Participation of Wallonia
The EANM 2024 edition attracted nearly 180 exhibitors and 8,641 participants. This year, nine companies will be present on the Wallonia Export & Investment Agency island booth of 132 m². A strong Walloon presence (alongside the individual booths for companies such as IBA, Trasis and Telix), significantly enhances its global visibility in both entrepreneurship and foreign investment potential. EANM is the ideal platform for nuclear medicine companies to grow their business and forge partnerships. It is also a prime opportunity to promote Wallonia as an attractive and strategic location for innovative radiopharma SMEs—with a particular focus on theranostics—as well as for production actors, building on its unique strengths.
The nine companies on AWEX’ booth are:
ABSCINT
Abscint specializes in advanced in vivo imaging diagnostics, focusing on developing innovative PET tracers using single-domain antibodies (sdAbs) for precision targeting.
DIASOURCE IMMUNOASSAYS
Diasource ImmunoAssays is a diagnostics company specializing in endocrinology and autoimmune diseases. DIAsource also provides decontamination products for labs and nuclear medicine, delivering a comprehensive service to RIA users.
ELYSIA
Elysia provides LIMS, chromatography, and quality control systems to the pharmaceutical, agrochemical, and nuclear/PET industries.
At EANM 2025, Elysia will showcase its cutting-edge solutions for quality control and radiopharmaceutical production, combining hardware, software, and services to meet the strictest GMP/GLP laboratory requirements. “Our presence at EANM aims to strengthen our visibility, present our innovations, engage with users, and establish new partnerships.” — Daniel Barthélemy, CEO
FULL-LIFE TECHNOLOGY EUROPE
Full-Life Technologies is a fully integrated global radiotherapeutics company, committed to tackling the core challenges of today’s radiopharmaceuticals by pioneering research to shape tomorrow’s treatments.“Full-Life looks forward to presenting our latest progress in innovative radiopharmaceutical drug development and our Ac-225 manufacturing facility in Belgium. We are also eager to learn from the community and, together, accelerate development of the radiopharmaceutical field to benefit more patients worldwide.” — Frédéric Loncelle, Head of Full-Life HR Belgium
IRE ELiT
IRE ELiT, the innovation subsidiary of the Institute for Radioelements, is a radiopharmaceutical company founded in 2010. It develops radiopharmaceuticals for molecular imaging and targeted therapy. Its flagship product, the Ge-68/Ga-68 generator, is an innovative and simple PET imaging solution, primarily used for neuroendocrine tumors (NETs) and recurrent prostate cancer.
MODELLO ARCHITECTES
Modello Architectes has been providing architectural services since 2005, with a core focus on designing radiopharmacy and healthcare facilities.
At EANM, the firm will present its prototype radiopharmacy bunker, developed in collaboration with Tractebel. “We look forward to meeting potential builders of nuclear medicine infrastructures and exchanging updates with specialized suppliers in the sector.” — Gordian Roussel, Architect
SCANNIX
Scannix specializes in radiation protection and nuclear measurement instrumentation. Its portfolio includes electronic dosimeters, gamma cameras, CZT-based detectors, contamination monitors, radiation shielding, area monitors, isotope identifiers, and radiation portals. Scannix also provides calibration services and user training.
THE ONCIDIUM FOUNDATION
Oncidium foundation is a non-profit organization dedicated to supporting and accelerating the development of radiotheranostics for cancer care. It connects patients, practitioners, and nuclear medicine experts by raising awareness and improving global access to radioligand therapies (RLT).
VORTAL
Vortal is a leader in reusable, Type A-certified transport systems for radiopharmaceuticals.
